文献速递类风湿关节炎系统性红斑狼疮血管炎

风湿与自身免疫病中补体治疗格局的演变

The Evolving Landscape for Complement Therapeutics in Rheumatic and Autoimmune Diseases.
PubMed 文献 · Arthritis Rheumatol · 2017-10-17

本文综述补体系统在人类炎症与自身免疫病发病中的作用,阐述三条激活途径(经典、替代、凝集素)的机制与调控异常,并讨论已批准及在研补体抑制剂在非风湿与风湿病中的应用,以及通过生物标志物评估补体系统功能的方法。

要点

  • 补体系统在风湿与自身免疫病发病中起重要作用,商业开发补体抑制剂与效应通路调节药物的努力快速增加。
  • 综述涵盖经典、替代与凝集素三条补体激活途径的机制、正常调控及靶组织中的失调。
  • 已批准和在研补体治疗药物在非风湿与风湿病背景下讨论,并概述通过生物标志物评估补体系统的方法。

核心结论

  • 补体系统在人类炎症与自身免疫病发病中作用日益明确,补体抑制剂与效应通路调节药物的开发快速扩展。

研究设计与样本

  • 综述,检索范围未在摘要中报告。

主要发现

  • 综述阐述补体系统组分、三条激活途径(经典、替代、凝集素)的激活机制及正常调控与靶组织失调。
  • 综述说明部分疾病在很大程度上依赖补体,依据是补体治疗药物在患者中的成功开发与批准。
  • 综述举例说明类风湿关节炎、狼疮与血栓性微血管病中的补体激活机制。

关键数值与推荐

  • 已批准和在研的具体治疗药物在非风湿与风湿病背景下讨论,具体药物与数值未在摘要中报告。

临床怎么用

  • 可通过生物标志物研究评估人类补体系统功能,以理解特定患者中补体系统的运作方式。

局限性

  • 摘要未报告综述的检索范围与纳入标准。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The complement system is increasingly understood to play major roles in the pathogenesis of human inflammatory and autoimmune diseases. Because of this situation, there are rapidly expanding commercial efforts to develop novel complement inhibitors and effector pathway-modulating drugs. This review provides insights into the evolving understanding of the complement system components, mechanisms of activation within and across the 3 pathways (classical, alternative, and lectin), how the pathways are normally controlled and then dysregulated in target tissues, and what diseases are known to be, in large part, complement-dependent through the successful development and approval of complement therapeutics in patients. Mechanisms of complement activation in rheumatoid arthritis, lupus, and thrombotic microangiopathies are also illustrated. In addition, the specific therapeutic drugs that are both approved and under development are discussed in the context of both nonrheumatic and rheumatic diseases. Finally, the methods by which the complement system can be assessed in humans through biomarker studies are outlined, with the goal of understanding, in specific patients, how the system is functioning.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Thurman JM, Frazer-Abel A, Holers VM, et al. The Evolving Landscape for Complement Therapeutics in Rheumatic and Autoimmune Diseases. Arthritis Rheumatol. 2017. PMID: 28732131. doi:10.1002/art.40219

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。